Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Warren Website

Katherine E. Warren, M.D.

Selected Publications

1)  Warren KE, Patronas N, Aikin AA, Albert PS, Balis FM.
Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors.
J Natl Cancer Inst. 93: 1401-5, 2001.
2)  Lonser RR, Warren KE, Butman JA, Quezado Z, Robison RA, Walbridge S, Schiffman R, Merrill M, Walker ML, Park DM, Croteau D, Brady RO, Oldfield EH.
Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note.
J. Neurosurg. 107: 190-7, 2007.
3)  Hipp SJ, Steffen-Smith E, Hammoud D, Shih JH, Bent R, Warren KE.
Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging.
Neuro-oncology. 13: 904-9, 2011.
4)  Warren KE, Killian K, Suuriniemi M, Wang Y, Quezado M, Meltzer PS.
Genomic aberrations in pediatric diffuse intrinsic pontine gliomas.
Neuro-oncology. 14: 326-32, 2012.
5)  Fangusaro J, Warren KE.
Unclear standard of care for pediatric high grade glioma patients.
J. Neurooncol. 113: 341-2, 2013.
6)  Chittiboina P, Heiss JD, Warren KE, Lonser RR.
Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas.
J Neurosurg Pediatr. 13: 276-82, 2014.
7)  Steffen-Smith EA, Baker EH, Venzon D, Shandilya S, Bent RS, Warren KE.
Measurements of the pons as a biomarker of progression for pediatric DIPG.
J. Neurooncol. 116: 127-33, 2014.
8)  Fangusaro J, Gururangan S, Poussaint TY, McLendon RE, Onar-Thomas A, Warren KE, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Kun LE, Fouladi M.
Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022).
Cancer. 119: 4180-7, 2013.
9)  Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW.
Challenges With Defining Response to Antitumor Agents in Pediatric Neuro-Oncology: A Report From the Response Assessment in Pediatric Neuro-Oncology (RAPNO) Working Group.
Pediatr Blood Cancer. 60: 1397-401, 2013.
10)  McCully CM, Pastakia D, Bacher J, Thomas ML, Steffen-Smith EA, Saleem K, Murphy RF, Walbridge S, Brinster L, Widemann BC, Warren KE.
Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta).
Comp. Med. 63: 355-60, 2013.
11)  Ballester LY, Wang Z, Shandilya S, Miettinen M, Burger PC, Eberhart CG, Rodriguez FJ, Raabe E, Nazarian J, Warren K, Quezado MM.
Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas.
Am. J. Surg. Pathol. 37: 1357-64, 2013.
12)  Warren KE.
Novel therapeutic delivery approaches in development for pediatric gliomas.
CNS Oncol. 2: 427-435, 2013.
13)  Warren KE.
Novel therapeutic delivery approaches in development for pediatric gliomas.
Future Oncol. 2: 427-35, 2013.
14)  Wiener L, Sweeney C, Baird K, Merchant MS, Warren KE, Corner GW, Roberts KE, Lichtenthal WG.
What Do Parents Want to Know When Considering Autopsy for Their Child With Cancer?.
J. Pediatr. Hematol. Oncol. [Epub ahead of print], 2013.
15)  Warren KE, Gururangan S, Geyer JR, McLendon RE, Poussaint TY, Wallace D, Balis FM, Berg SL, Packer RJ, Goldman S, Minturn JE, Pollack IF, Boyett JM, Kun LE.
A phase II study of O6-benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study.
J. Neurooncol. 106: 643-9, 2012.
16)  Warren KE.
Diffuse intrinsic pontine glioma: poised for progress.
Front Oncol. 2: 205, 2012.
17)  Martin S, Calabrese SK, Wolters PL, Walker KA, Warren K, Hazra R.
Family functioning and coping styles in families of children with cancer and HIV disease.
Clin Pediatr (Phila). 51: 58-64, 2012.
18)  Hipp SJ, Steffen-Smith EA, Patronas N, Herscovitch P, Solomon JM, Bent RS, Steinberg SM, Warren KE.
Molecular imaging of pediatric brain tumors: comparison of tumor metabolism using (18)F-FDG-PET and MRSI.
J Neurooncol. 109: 521-7, 2012.
19)  Ko C, Kaushal A, Hammoud DA, Steffen-Smith EA, Bent R, Citrin D, Camphausen K, Warren KE.
Role of Early Postradiation Magnetic Resonance Imaging Scans in Children with Diffuse Intrinsic Pontine Glioma.
Int J Radiat Oncol Biol Phys. 83: 1252-6, 2012.
20)  Steffen-Smith EA, Venzon DJ, Bent RS, Hipp SJ, Warren KE.
Single- and Multivoxel Proton Spectroscopy in Pediatric Patients With Diffuse Intrinsic Pontine Glioma.
Int J Radiat Oncol Biol Phys. 84: 774-9, 2012.
21)  Warren K, Bent R, Wolters PL, Prager A, Hanson R, Packer R, Shih J, Camphausen K.
A phase 2 study of pegylated interferon α-2b (PEG-Intron®) in children with diffuse intrinsic pontine glioma.
Cancer. 118: 3607-13, 2011.
22)  Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE.
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
J. Clin. Oncol. 29: 324-9, 2011.
23)  Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE.
Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma.
J Neurooncol. 105: 365-73, 2011.
24)  Marcus L, Murphy R, Fox E, McCully C, Cruz R, Warren KE, Meyer T, McNiff E, Balis FM, Widemann BC.
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates.
Cancer Chemother Pharmacol. 69: 247-52, 2011.
25)  Asthagiri A, Warren K, Lonser R.
Kaye A, Laws, Jr E, eds.
Brain tumors associated with neurofibromatosis. In: Brain Tumors. Volume third edition.
2010. In Press. [Book Chapter]
26)  Warren K, Lonser R.
Kaye A, Laws, Jr. E, eds.
Brainstem Gliomas. In: Brain Tumors. Volume Third Edition.
2010. In Press. [Book Chapter]
27)  Warren K, Young H.
The role of interferons in cancer therapy.
Current Drug Therapy. 5: 132-138, 2010.
28)  Warren KE.
Noninvasive assessment of pediatric brain tumors.
Cancer Biol. Ther. 8: 1881-8, 2009.
29)  Meany HJ, Warren KE, Fox E, Cole DE, Aikin AA, Balis FM.
Pharmacokinetics of temozolomide administered in combination with O(6)-benzylguanine in children and adolescents with refractory solid tumors.
Cancer Chemother. Pharmacol. 2009.
30)  Fitzhugh CD, Wise B, Baird K, Tsokos M, Helman L, Mackall C, Savage SA, Warren KE.
Secondary supratentorial primitive neuroectodermal tumor following treatment of childhood osteosarcoma.
Pediatr Blood Cancer. 53: 496-8, 2009.
31)  Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC.
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
Oncologist. 13: 679-89, 2008.
32)  Steffen-Smith EA, Wolters PL, Albert PS, Baker EH, Shimoda KC, Barnett AS, Warren KE.
Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.
Childs Nerv Syst. 24: 807-13, 2008.
33)  Hayward RM, Patronas N, Baker EH, Vezina G, Albert PS, Warren KE.
Inter-observer variability in the measurement of diffuse intrinsic pontine gliomas.
J. Neurooncol. 90: 57-61, 2008.
34)  Warren KE, McCully C, Dvinge H, Tjornelund J, Sehested M, Lichenstein HS, Balis FM.
Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates.
Cancer Chemother. Pharmacol. 62: 433-7, 2008.
35)  Warren K, Jakacki R, Widemann B, Aikin A, Libucha M, Packer R, Vezina G, Reaman G, Shaw D, Krailo M, Osborne C, Cehelsky J, Caldwell D, Stanwood J, Steinberg SM, Balis FM.
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
Cancer Chemother. Pharmacol. 58: 343-7, 2006.
36)  Warren KE.
Advances in the Assessment of Childhood Brain Tumors and Treatment-Related Sequelae.
Curr Neurol Neurosci Rep. 5: 119-26, 2005.
37)  Warren KE, Aikin AA, Libucha M, Widemann BC, Fox E, Packer RJ, Balis FM.
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
J. Clin. Oncol. 23: 7646-53, 2005.
38)  Solomon J, Warren K, Dombi E, Patronas N, Widemann B.
Automated Detection and Volume Measurement of Plexiform Neurofibromas in Neurofibromatosis I using Magnetic Resonance Imaging.
Comput Med Imaging Graph. 28: 257-265, 2004.
39)  Warren KE, Packer RJ.
Current approaches to CNS tumors in infants and very young children.
Expert Rev Neurother. 4: 681-90, 2004.
40)  Warren KE.
NMR Spectroscopy and Pediatric Brain Tumors.
Oncologist. 9: 312-8, 2004.
41)  Warren K, Gervais A, Aikin A, Egorin M, Balis FM.
Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Cancer Chemother Pharmacol. 54: 206-212, 2004.
42)  Warren KE.
Proton Magnetic Resonance Spectroscopic Imaging in Children with Primary Brain Tumors.
The Oncologist. 9: 312-318, 2004.
43)  Lutz RJ, Warren K, Balis F, Patronas N, Dedrick RL.
Mixing during intravertebral arterial infusions in an in vitro model.
J Neurooncol. 58: 95-106, 2002.
44)  Warren KE, Patel MC, Aikin AA, Widemann B, Libucha M, Adamson PC, Neuwirth R, Benziger D, O'Toole T, Ford K, Patronas N, Packer RJ, Balis FM.
Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors.
Cancer Chemother Pharmacol. 48: 275-82, 2001.
45)  Warren KE, McCully CM, Walsh TJ, Balis FM.
Effect of fluconazole on the pharmacokinetics of doxorubicin in nonhuman primates.
Antimicrob Agents Chemother. 44: 1100-1, 2000.
46)  Warren KE, Patel MC, McCully CM, Montuenga LM, Balis FM.
Effect of the P-glycoprotein inhibitor, Cyclosporin A, on the cerebrospinal fluid penetration of Doxorubicin.
Cancer Chemother Pharmacol. 45: 207-212, 2000.
47)  Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, Balis FM, Bauer K, Raffeld M, Senderowicz AM, Monks A.
Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
Clin Cancer Res. 6: 415-21, 2000.
48)  Kinsella TJ, Schupp JE, Davis TW, Berry SE, Hwang HS, Warren K, Balis F, Barnett J, Sands H.
Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Clin Cancer Res. 6: 3670-9, 2000.
49)  Warren KE, Frank JA, Black JL, Hill RS, Duyn JH, Aikin AA, Lewis BK, Adamson PC, Balis FM.
Proton magnetic resonance spectroscopic imaging in children with recurrent primary brain tumors.
J Clin Oncol. 18: 1020-6, 2000.
50)  Warren KE, Gidvani-Diaz V, Duval-Arnould B.
Renal medullary carcinoma in an adolescent with sickle cell trait.
Pediatrics. 103: E22, 1999.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/17/2014.